Luvixasertib

DB19200InvestigationalSmall molecule

Luvixasertib is under investigation in clinical trial NCT05251714 (CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer).

Chemical structure of Luvixasertib
Formula / weight
C28H30N6O3 · 498.587 g/mol (avg)
Also known as
Benzamide, n-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methyl- · N-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methylbenzamide
Code names
CFI-402257

Resolves to

Compound
UNIIHE97PTK3Q6CAS1610759-22-2ChEMBLCHEMBL4469414
Structure
InChIKeyPMQUGSPFUBGJCZ-CHOKWEPUSA-NSMILESCC1=CC(=CC=C1C(=O)NC1CC1)C1=C2N=C(OC3=CC=CN=C3)C=C(NC[C@H]3C[C@@](C)(O)C3)N2N=C1
Targets
P33981TTK

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Luvixasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In